Derlin-1 functions as a growth promoter in breast cancer.

In this study, we found that Derlin-1 overexpression was higher in breast cancer compared to normal samples through TCGA and GTEx database analyses. Kaplan-Meier plotter analysis showed that Derlin-1 was a predicting factor for patient prognosis. Derlin-1 expression was significantly up-regulated in breast cancer tissues (18/30, 60.00%) compared to corresponding paracancerous tissue (9/30, 30.00%, p 
Source: Biological Chemistry - Category: Chemistry Tags: Biol Chem Source Type: research

Related Links:

New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - Category: Internal Medicine Authors: Source Type: research
os AC Abstract PURPOSE: To examine the effects of Arrabidaa chica (Bignoniacea) extract, a native plant of the Amazon known as crajiru, on a 7,12-dimethyl-1,2-benzanthracene (DMBA)-induced breast cancer model in Wistar rats. METHODS: We compared the response of breast cancer to the oral administration of A. chica extract (ACE) for 16 weeks, associated or not with vincristine. Groups: normal control; DMBA (50mg/kg v.o,) without treatment; DMBA+ACE (300 mg/kg); DMBA+vincristine. 500μg/kg injected i.p; DMBA+ACE+Vincristine 250μg/kg i.p. Imaging by microPET and fluorescence, biochemistry, oxidative stress, ...
Source: Acta Cirurgica Brasileira - Category: Surgery Authors: Tags: Acta Cir Bras Source Type: research
Triple-negative breast cancer is difficult to treat. A new study indicates that a common chemotherapy drug improves overall survival in this tumor type -- big news in cancer treatment.Medscape Medical News
Source: Medscape General Surgery Headlines - Category: Surgery Tags: Hematology-Oncology News Source Type: news
Publication date: Available online 21 November 2019Source: Best Practice &Research Clinical Obstetrics &GynaecologyAuthor(s): Mangesh A. Thorat, Rajeshkumar BalasubramanianAbstractWomen at high risk of developing breast cancer are a heterogeneous group of women including those with and without high-risk germline mutation/s. Prevention in these women requires a personalised and multidisciplinary approach. Preventive therapy with selective oestrogen receptor modulators (SERMs) like tamoxifen and aromatase inhibitors (AIs) substantially reduces breast cancer risk well beyond the active treatment period. The importance...
Source: Best Practice and Research Clinical Obstetrics and Gynaecology - Category: OBGYN Source Type: research
FoundationOne CDx has earned yet another approval from FDA, making the companion diagnostic now available for 19 FDA-approved targeted therapies. It can now be used as a companion diagnostic for Piqray (alpelisib) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. FDA approved Piqray in May 2019, and it is the first and only treatment specifically for patients with a PIK3CA mutation i...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
This study was conducted in 263,788 women aged 40–69 years at enrolment into the UK Biobank population-based cohort. Information on demographic, reproductive and health factors was collected at baseline using computerized questionnaires, while incident DCIS was ascertained through linkage to UK cancer registries. Age-adjusted and multivariable hazard ratios were estimated using Cox proportional hazards models in the total sample and by menopausal status. During an average of 7 years of follow-up, 1,016 women developed DCIS. Multivariable analysis indicated that age, physical activity, height, family history of breast...
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
We describe a feature, give a location, and then synthesise a conclusion. For example: There is an irregular mass with microcalcification in the upper outer quadrant of the breast. Findings are consistent with malignancy. You don’t need to understand the words I used here, but the point is that the features (irregular mass, microcalcification) are consistent with the diagnosis (breast cancer, malignancy). A doctor reading this report already sees internal consistency, and that reassures them that the report isn’t wrong. An common example of a wrong report could be: Irregular mass or microcalcificat...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Artificial Intelligence Health Tech AI Luke Oakden-Rayner machine learning Radiology Source Type: blogs
CONCLUSIONS: Breast carcinosarcoma is a rare subtype of metaplastic breast cancer. It is characterised by large tumour size, higher rates of axillary nodal involvement, higher rates of both local and distant recurrence, and is difficult to diagnose with preoperative core needle biopsies. Adjuvant treatment after surgical operation may improve the five-year OS of patients with breast carcinosarcoma. PMID: 31820860 [PubMed - in process]
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemistry | Databases & Libraries | Genetics | Study | Women